Title: Phase 2 KEYNOTE‐B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B‐cell lymphoma (PMBCL).
Authors: McDonald, A.; Verburgh, E.; Gotti, M.; Pinto, A.; Zaucha, J.; Ivanov, V.; Melnichenko, V.; Mocikova, H.; Ozcan, M.; Patti, C.; Farias, J.; Goncalves, I.; Kuchkova, O.; Mayer, J.; Saydam, G.; Tomassetti, S.; Pathiraja, K.; Ryland, K.; Chakraborty, S.; Jurczak, W.
Abstract: B Conclusions: b With approximately 9 mo of follow-up, pembro 400 mg Q6W had robust antitumor activity in pts with R/R cHL and R/R PMBCL, with ORR similar to that with pembro 200 mg Q3W. B Introduction: b Pembrolizumab (pembro) was originally approved by the FDA for the treatment of R/R cHL and R/R PMBCL at 200 mg every 3 weeks (Q3W). Treatment-related AEs occurred in 24 pts (40%) with R/R cHL and 2 (33.3%) with R/R PMBCL; grade >=3 treatment-related AEs occurred in 3 pts (5%) and 1 pt (16.7%), respectively.
Subjects: HODGKIN'S disease; LYMPHOMAS; PEMBROLIZUMAB
Publication: Hematological Oncology, 2023, Vol 41, p575
ISSN: 0278-0232
Publication type: Academic Journal
DOI: 10.1002/hon.3164_431

Phase 2 KEYNOTE‐B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B‐cell lymphoma (PMBCL).

McDonald, A.; Verburgh, E.; Gotti, M.; Pinto, A.; Zaucha, J.; Ivanov, V.; Melnichenko, V.; Mocikova, H.; Ozcan, M.; Patti, C.; Farias, J.; Goncalves, I.; Kuchkova, O.; Mayer, J.; Saydam, G.; Tomassetti, S.; Pathiraja, K.; Ryland, K.; Chakraborty, S.; Jurczak, W.